QIAGEN (QGEN)
(Real Time Quote from BATS)
$43.14 USD
-0.91 (-2.07%)
Updated Nov 6, 2025 11:34 AM ET
3-Hold of 5 3
C Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, QIAGEN N.V. has a PEG ratio of 1.90 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.46.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QGEN 43.14 -0.91(-2.07%)
Will QGEN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for QGEN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for QGEN
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
QGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
QGEN or EXAS: Which Is the Better Value Stock Right Now?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Other News for QGEN
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Qiagen (QGEN) and Xtant Medical Holdings (XTNT)
QGEN forms 200 Day Moving Average Resistance on November 5
Qiagen price target lowered to $46 from $49 at Baird
Qiagen price target lowered by $3 at Baird, here's why
QIAGEN Announces Q3 Results, Parse Acquisition, and Share Repurchase